Innovative Diagnostic Platform Velox Biosystems offers a cutting-edge digital droplet technology (IC3D) that simplifies and accelerates pathogen detection and biomarker monitoring, making it highly attractive for laboratories seeking rapid, reliable diagnostics.

Expanding COVID-19 Testing Capabilities The company’s recent launch of a serological testing service highlights an opportunity to collaborate on expanding COVID-19 testing solutions and other infectious disease diagnostics, appealing to healthcare providers and public health institutions.

Growth Potential in Biotechnology With a current revenue under 1 million dollars but significant technological advancements, Velox presents a growth opportunity for partners looking to invest in innovative biotech startups with scalable diagnostic platforms.

Targeting Niche Market Segments The company’s ability to process raw samples directly and its focus on detecting a range of pathogenic agents positions it well to serve specialized markets such as neurology, oncology, and infectious diseases, offering tailored sales approaches.

Technology-Driven Differentiation Velox’s fully automated, high-sensitivity digital droplet technology can differentiate it from traditional lab methods, making it an appealing partner for organizations seeking to enhance their diagnostic capabilities with innovative tech solutions.